-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SThQmUN7jMlw1sER6h215nkcZVIOVn0EWrbf5UxqQUpDkHmoM7V+QNMhQWA4Wmfn 7B4OPl/NJy8QeJE8bsLaAw== 0000950129-08-006173.txt : 20090406 0000950129-08-006173.hdr.sgml : 20090406 20081229123923 ACCESSION NUMBER: 0000950129-08-006173 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20081229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 CORRESP 1 filename1.htm corresp
December 29, 2008
Direct dial: (281) 681-5934
paubert@winstead.com
Ms. Sasha S. Parikh
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re:   Repros Therapeutics Inc.
Extension for Response
File No. 1-15281
Dear Ms. Parikh:
Reference is made to that certain letter received by our client, Repros Therapeutics Inc. from the Securities and Exchange Commission (“SEC”) dated December 22, 2008. This letter will confirm the telephone conversation between Louis Ploth, Jr., VP and CFO of Repros Therapeutics Inc., and you, during which Repros informally requested an extension to respond to the above-referenced letter until January 23, 2009, due to its staffs’ and consultants’ holiday and vacation schedules and other previously-scheduled business engagements. Accordingly, please accept this letter as written confirmation of Repros’ request to extend the deadline to respond to the above-referenced letter to January 23, 2009.
If you have any questions, please feel free to contact me at 281.681.5934.
         
  Sincerely yours,
 		  
  /s/ Paul D. Aubert    
  Paul D. Aubert   
     
 
PDA/jms
 
cc: Louis Ploth, Repros Therapeutics Inc.

-----END PRIVACY-ENHANCED MESSAGE-----